GOUTY ARTHRITIS – MODERN VIEW OF THE PROBLEM
https://doi.org/10.21518/2079-701X-2017-17-106-112
Abstract
Gout is a fairly common rheumatic disease, the significance of which becomes an increasingly important interdisciplinary problem. It is known that about 2.5% of men over the age of 30 and women over the age of 50 suffer from gout. By the age of 80 y.o. the disease is registered already in 9% of men and 6% women. The increased incidence, high comorbidity, and low compliance of patients with gout put new questions when the adequate complex therapy is sought.
Despite the fact that the treatment of this disease is well known and widely discussed in the literature, it’s possible to achieve remission of gout only in very rare cases. In the literature, there is evidence that less than ½ of patients with gout get ordinary therapy, while often drugs are prescribed in doses not sufficient to obtain the effect [1].
About the Authors
V. I. Mazurov
Mechnikov North-Western State Medical University
Russian Federation
Russian Federation
RAS academician, MD, Prof.
Saint-PetersburgM. S. Petrova
Mechnikov North-Western State Medical University
Russian Federation
Russian Federation
PhD in medicine.
Saint-Petersburg
O. V. Inamova
Mechnikov North-Western State Medical University
Russian Federation
Russian Federation
PhD in medicine.
Saint-Petersburg
M. M. Museichuk
Mechnikov North-Western State Medical University
Russian Federation
Russian Federation
Saint-Petersburg
References
1. Richette P, Doherty M, Pascual E et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases, 2017, 76: 29-42.
2. Pillinger MH, Rosenthal P, Abeles AM. Hyperuricemia and gout. New insights into pathogenesis and treatment. Bulletin of the NYU Hospital for Joint Diseases, 2007, 65(3): 215-221.
3. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Annals of Internal Medicine. 2005, 143: 499-516.
4. Sanderson IR, He Y. Nucleotide uptake and metabolism by intestinal epithelial cells. The Journal of Nutrition, 1994 January, 124: 124S-160S.
5. Sonoda T, Tatibana M. Metabolic fate of pyrimidines and purines in dietary nucleic acids ingested by mice. Biochimica et Biophysica Acta (BBA), 1978, 521: 55-66.
6. Terkeltaub R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis if hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Research and Therapy, 2006, 8(Suppl 1): S4.
7. Sorensen LB. Degradation of uric acid in man. Metabolism, 1959, 8: 687-703.
8. Rudolph FB. The biochemistry and physiology of nucleotides. The Journal of Nutrition, 1994 January, 124: 124S-160S.
9. Mikuls TR, Farrar JT, Bilker WB et al. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis, 2005 Feb, 64(2): 267-72.
10. Kutzing MK, Firestein BL. Altered uric acid levels and disease states. The Journal of Pharmacology and Experimental Therapeutics, 2008, 324: 1-7.
11. So A. Developments in the scientific and clinical understanding of gout. Arthritis Research & Therapy, 2008, 10: 221.
12. Liu-Bryan R, Terkeltaub R. Evil humors take their toll as innate immunity makes gouty joints TREM-ble. Arthritis & Rheumatism, 2006 Feb, 54(2): 383-386.
13. Murakami Y, Akahoshi T, Hayashi I, Endo H, Kawai S, Inoue M, Kondo H, Kitasato H. Induction of Triggering receptor expressed on myeloid cells 1 in murine resident peritoneal macrophages by monosodium urate monohydrate crystals. Arthritis & Rheumatism, 2006 Feb, 54(2): 455-462.
14. Martinon F. Mechanisms of uric acid crystalmediated autoinflammation. Immunological Reviews, 2010, 233: 218-232.
15. Заболеваемость населения России (в 2000–2006 гг.). Статистические материалы Министерства здравоохранения и социального развития РФ (за 2001–2007 гг.).
16. Dalbeth N, Stamp L. Hyperuricaemia and gout: time for a new staging system? Ann Rheum Dis, 2014, 73: 1598-600. doi:10.1136/annrheumdis-2014-205304.
17. Grassi W, Meenagh G, Pascual E, Filippucci E. Crystal clear-sonographic assessment of gout and calcium pyrophosphate deposition disease. Semin Arthritis Rheum, 2006, 36(3): 197-202.
18. Nicolaou S, Yong-Hing C, Galea-Soler S, Hou D, Louis L, Munk P. Dual-energy CT as a potential new diagnostic tool in the management of gout in the acute setting. Am J Roentgenol, 2010, 194: 1072-1078.
19. Choi H, Burns L, Shojania K, Koenig N, Reid G, Abufayyah M et al. Dual energy CT in gout: a prospective validation study. Ann Rheum Dis, 2012, 71: 1466-1471.
20. Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Annals Epidemiol, 1998, 8: 250-261. doi: 10.1016/S1047-2797(97)00204-4.
21. Moi JH, Sriranganathan MK, Falzon L et al. Lifestyle interventions for the treatment of gout: a summary of 2 Cochrane systematic reviews. J Rheumatol, 2014, 92(Suppl): 26-32. doi:10.3899/jrheum.140459.
22. Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol, 2011, 23: 192-202. doi:10.1097/BOR.0b013e3283438e13.
23. Yamanaka H. Gout and hyperuricemia in young people. Curr Opin Rheumatol, 2011, 23: 156-160. doi:10.1097/BOR.0b013e3283432d35.
24. Baker JF, Schumacher HR, Krishnan E. Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial. Angiology, 2007, 58: 450-457. doi:10.1177/0003319707303444.
25. Jalal DI, Chonchol M, Chen W et al. Uric acid as a target of therapy in CKD. Am J Kidney Dis, 2013, 61: 134-146. doi:10.1053/j.ajkd.2012.07.021.
26. Schlesinger N, Mysler E, Lin HY et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomized study. Ann Rheum Dis, 2011 Jul, 70(7): 1264-1271.
27. Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich), 2013, 15: 435-442. doi:10.1111/j.1751-7176.2012.00701.x.
28. Goicoechea M, Garcia de Vinuesa S, Verdalles U et al. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. Am J Kidney Dis, 2015, 65: 543-549. doi:10.1053/j.ajkd.2014.11.016.
29. Saag KG, Whelton A, Becker MA et al. Impact of febuxostat on renal function in gout subjects with moderate-to-severe renal impairment. Arthritis Rheumatol, 2016. [Epub ahead of print 19 Feb 2016]. doi:10.1002/art.39654doi:10.1002/art.39654.
Review
For citations:
Mazurov VI, Petrova MS, Inamova OV, Museichuk MM. GOUTY ARTHRITIS – MODERN VIEW OF THE PROBLEM. Meditsinskiy sovet = Medical Council. 2017;(17):106-112. (In Russ.) https://doi.org/10.21518/2079-701X-2017-17-106-112
Views:
731
Email this article 